Cronos Group Inc. (TSE:CRON - Get Free Report)'s stock price shot up 9% during mid-day trading on Wednesday . The stock traded as high as C$2.91 and last traded at C$2.91. 73,241 shares were traded during trading, a decline of 30% from the average session volume of 104,087 shares. The stock had previously closed at C$2.67.
Cronos Group Price Performance
The stock has a 50-day simple moving average of C$2.81 and a 200 day simple moving average of C$2.96. The company has a current ratio of 28.29, a quick ratio of 24.01 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of C$1.06 billion, a price-to-earnings ratio of -13.24, a price-to-earnings-growth ratio of 0.12 and a beta of 1.02.
Cronos Group Company Profile
(
Get Free Report)
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth.
Read More
Before you consider Cronos Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cronos Group wasn't on the list.
While Cronos Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.